Insider Trades: 17 ASX 200 directors bought and sold these stocks last week
Insiders from Wisetech, Neuren and Pantoro offloaded millions last week, while directors from Mesoblast and Bapcor bought the dip.
Source: iStock
Mentioned
Welcome back to the Insider Trades series – a weekly summary of on-market ASX 200 director transactions valued at more than $10,000. The below trades have all taken place between 4 and 12 September 2025. Directors have up to 5 business days to notify the ASX of their trades.
Top ASX 200 Insider Buys
Code | Company | Date | Director | Price | Value |
|---|---|---|---|---|---|
Mesoblast | 11/09/25 | NA | US$18,848,476 | ||
GQG Partners | 8/09/25 | $1.77 | $530,658 | ||
GQG Partners | 10/09/25 | $1.72 | $516,738 | ||
GQG Partners | 5/09/25 | $1.75 | $359,331 | ||
South32 | 12/09/25 | $2.61 | $260,950 | ||
Pinnacle | 12/09/25 | $18.79 | $46,035 | ||
Flight Centre | 10/9/25 | $12.14
| $24,280 | ||
Rio Tinto | 12/09/25 | $114.93 | $22,986 | ||
Super Retail Group | 5/09/25 | $18.52 | $18,520 | ||
Bapcor | 9/09/25 | $3.50 | $15,750 | ||
Bendigo and Adelaide Bank | 5/09/25 | $12.53 | $13,783 | ||
Brambles | 9/09/25 | $26.13 | $13,065 |
Key takeaways
Mesoblast: Non-Executive Director Dr Gregory George purchased US$18 million worth of ADRs on the NYSE. Dr George founded and managed a privately owned ambulatory surgical center company in the US. The stock has traded sideways in recent months following a massive July rally that was offset by a selloff during August reporting season. The company is advancing multiple clinical trials this quarter, including an adult acute GvHD study with the NIH-funded CTN Group and IBD trial design updates, while targeting Q1 2026 completion for their Phase 3 chronic lower back pain trial.
GQG Partners: Chief Investment Officer Rajiv Jain continues to acquire shares via QVFT LLC, an entity controlled by Jain and GQG's parent organisation.
Bapcor: CEO Angus McKay purchased a small parcel following the company's challenging period. Bapcor pre-released weaker earnings on 24 July, triggering a sharp 28% selloff due to revenue pressure across all divisions and material balance sheet writedowns. Analysts viewed the update as a setback in the company's turnaround efforts, with execution risk and poor transparency driving cautious sentiment. The stock has continued declining, falling an additional 8% since the initial selloff.
All the other trades were made by Non-Executive directors.
Top ASX 200 Insider Sells
Code | Company | Date | Director | Price | Value |
|---|---|---|---|---|---|
Wisetech Global | 4/09/25 | $98.17 | $69,042,961 | ||
Wisetech Global | 11/09/25 | $94.23 | $51,892,461 | ||
Neuren Pharmaceuticals | 8/09/25 | $20.00 | $7,964,140 | ||
Pantoro | 11/09/25 | $4.89 | $4,601,455 | ||
Perseus Mining | 5/09/25 | $4.11 | $6,165,000 | ||
Harvey Norman | 5/09/25 | $7.45 | $1,173,056 | ||
Pexa Group | 5/09/25 | $15.99 | $1,120,586 | ||
Region Group | 5/09/25 | $2.42 | $272,683 |
Key takeaways
Wisetech: Executive Chairman and founder Richard White sold over $120 million worth of shares in recent weeks, marking the first major selldown since October 2024. White typically sells shares gradually, previously stating he prefers "small daily trades in a very orderly way" to provide market liquidity.
Neuren: CEO Jon Pilcher sold approximately 21% of his holdings as the stock bounces back toward 14-month highs. The stock rallied 5.3% on its FY25 result day (27 August), with Macquarie analysts noting strong cash position enabling pipeline acceleration and potential long-term upside if approvals are secured.
Gold sector: Its interesting to see Perseus CEO Jeffrey Quartermaine and Pantoro Non-Executive Director Mark Maloney both sold into recent strength.
